Bullfrog

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

Retrieved on: 
Friday, March 8, 2024

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.

Key Points: 
  • GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.
  • This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).
  • The recording can be accessed via the following link: https://youtu.be/40rogXtHBJ8
    The fireside chat provided a deep dive into the early findings from the collaboration between BullFrog AI and LIBD.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.

BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

Retrieved on: 
Monday, February 26, 2024

Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.

Key Points: 
  • Prior to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific Machine Learning (SciML) Research and Development Initiative at HiberCell.
  • At BullFrog AI, Dr. Chittenden will lead the scientific strategy to further develop and implement cutting-edge AI-driven platforms for drug discovery and development.
  • Dr. Chittenden commented, "I am thrilled to join BullFrog AI and to contribute to the Company's innovative approach to drug development.
  • Dr. Chittenden's appointment as Chief Scientific Officer of BullFrog AI, effective February 26, 2024, marks a significant milestone for the Company as it continues to pioneer a new era of AI technology-enabled drug development.

BullFrog AI Announces Underwriter’s Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company’s Common Stock

Retrieved on: 
Wednesday, February 21, 2024

A registration statement on Form S-1 (File No.

Key Points: 
  • A registration statement on Form S-1 (File No.
  • 333-276740) relating to the securities was filed with the Securities and Exchange Commission (“SEC”) and became effective on January 31, 2024.
  • This offering was made only by means of a prospectus.
  • In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC’s website at www.sec.gov .

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

Retrieved on: 
Friday, February 9, 2024

The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Key Points: 
  • The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
  • For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.
  • To participate in the fireside chat, please register at:

BullFrog AI Announces Closing of $5.7 Million Public Offering

Retrieved on: 
Monday, February 5, 2024

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Key Points: 
  • The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
  • The offering has closed as all customary closing conditions have been satisfied.
  • WallachBeth Capital, LLC acted as sole book-running manager for the offering.
  • In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov .

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

Retrieved on: 
Thursday, February 1, 2024

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Key Points: 
  • The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
  • The offering is expected to close on February 5, 2024, subject to satisfaction of customary closing conditions.
  • WallachBeth Capital, LLC is acting as sole book-running manager for the offering.
  • In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov .

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

Retrieved on: 
Friday, January 26, 2024

“We are thrilled to welcome Dr. Smith and Dr. Wala to our advisory board,” said Vin Singh, CEO of BullFrog AI.

Key Points: 
  • “We are thrilled to welcome Dr. Smith and Dr. Wala to our advisory board,” said Vin Singh, CEO of BullFrog AI.
  • “I am honored to join the advisory board of BullFrog AI, a company that stands at the forefront of a transformative wave in the biopharma industry,” said Dr. Smith.
  • “BullFrog AI’s partnership with the Lieber Institute is poised to revolutionize our understanding and treatment of psychiatric and neurological conditions.
  • Dr. Wala commented, “I’m excited to work with BullFrog AI and to apply their novel AI platform in the oncology space.

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

Retrieved on: 
Wednesday, January 17, 2024

The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Key Points: 
  • The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
  • “This collaboration marks a pivotal moment in psychiatric research,” said Vin Singh, CEO of BullFrog AI.
  • “By employing our bfLEAP™ platform on LIBD’s unrivaled brain data, we’ve gained invaluable ground into unraveling the biological underpinnings of psychiatric disorders.
  • This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders.

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Retrieved on: 
Tuesday, January 16, 2024

2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.

Key Points: 
  • 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.
  • This follows the July 2023 announcement of the issuance of U.S. Patent No.
  • 11,712,435 for this invention ( link ), with issuance of patents expected in additional territories in the future.
  • "This patent grant further strengthens intellectual property protection of this key asset in our pipeline," said Vin Singh, founder and CEO of BullFrog AI.

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

Retrieved on: 
Thursday, January 11, 2024

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Chief Executive Officer of BullFrog AI, will present at the Webull LIVE!

Key Points: 
  • GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Chief Executive Officer of BullFrog AI, will present at the Webull LIVE!
  • Healthcare Webinar on Wednesday, January 17, 2024.